Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sertraline + cytarabine
- Development stage
- Phase 1
- Lead developer
- Columbia University Irving Medical Center
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
sertraline + cytarabine is a combination therapy being investigated by Columbia University for the treatment of relapsed and refractory acute myeloid leukemia (AML). The regimen combines sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI) typically used as an antidepressant, with cytarabine (ara-C), a standard antimetabolite chemotherapy agent. This approach is based on the concept of tumor reversion, where sertraline is repurposed to potentially sensitize leukemia cells to the apoptotic effects of cytarabine by addressing cell cycle dysregulation and DNA damage repair aberrations. The therapy is administered in a timed-sequential manner and is currently being evaluated in a Phase I clinical trial to determine safety, tolerability, and the maximum tolerated dose in adults with treatment-resistant myeloid leukemia.
- Other names
- sertraline + cytosine arabinosideZoloft + Ara-Csertraline and cytarabine
02
Targets
ABCC10 (Multidrug resistance-associated protein 7)DNA polymerase familySERT (Sodium-dependent serotonin transporter)TPT1 (Translationally-controlled tumor protein)DNA
Beyond the preview
Go deeper on sertraline + cytarabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sertraline + cytarabine.